上海
分享至
奥赛康近期投资者关系活动记录表显示，艾沙康唑已提交上市申请，有望于2024年获批上市。德拉沙星在临床III期进展中。
特别声明：以上内容(如有图片或视频亦包括在内)为自媒体平台“网易号”用户上传并发布，本平台仅提供信息存储服务。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.
